Chris MacDonald

Chris MacDonald

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

MoffettNathanson Is Souring on Roku Stock

ROKU stock is getting hammered today as analysts from MoffettNathanson downgrade the stock. Here's what to know.

It’s Time to Drop Lucid Stock Like a Hot Potato

Now's not the time for investors to get cute when it comes to LCID stock. There are other better EV names to consider in this current market.

C3.ai Stock Alert: Should You Invest Before 2023 Ends?

This top AI stock is among the few pure-play options for investors considering this space. But is it worth buying right now?

How Confident Should Nvidia Investors Be Heading Into 2024?

Is now the time to go all in on Nvidia and NVDA stock, considering how well the stock has done this year? Or is it best to be patient?

The Grinch That Stole the Christmas Rally: 3 Cryptos to Avoid Now

The list of cryptos to avoid is a relatively long one, but these in particular should be shunned this holiday season.

The Bull and Bear Case for Rivian (RIVN) Stock

Investors in Rivian and RIVN stock have plenty of risks to consider, but is this emerging electric vehicle player worth considering now?

Should You Buy Palantir Stock Before Dec. 31?

Palantir has been a clear winner from the surge in interest around AI stock. But can this company continue its impressive rally into 2024?

MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer

Moderna is in focus after reporting positive results for its cancer treatment today, with MRNA stock surging more than 9%.

Year-End IRA Contributions? 3 Stocks to Enhance Your Portfolio.

The list of companies is massive for those looking for IRA contribution stocks. Here are three top options to consider.

Bonk Price Predictions: How High Can a Coinbase Listing Take the BONK Crypto?

The Bonk crypto just scored a listing on Coinbase. What does that mean for the future of BONK price predictions? Let's take a look.